Lisa Lewin, Author at Precision Value & Health

PRECISIONscientia’s DOL Map named one of the most Innovative Products of 2022 by PM360 Magazine

Lisa Lewin2023-05-28T22:33:06+00:00News|

The continued growth of social and digital communications has ushered in new channels for the exchange of ideas and opinions. And now, these channels have given rise to new voices of influence—Digital Opinion Leaders (DOLs). To help pharma marketers identify and gain insights on DOLs in specific therapeutic areas, PRECISIONscientia has developed a powerful, web-based proprietary platform, DOL Map. The platform delivers an intuitive experience that summarizes each DOL’s impact, reach, and relevance to clients’ disease focus. DOL Map focuses on key components to find the right DOLs for any commercial brand or product in development: relevance, reach and audience engagement, impact on audience, and authenticity.

PRECISIONscientia’s DOL Map was named one of the most Innovative Products of 2022 by PM360 Magazine. Read the article HERE!

On-Demand: The Hitchhiker’s Guide to CGTx in 2023

Lisa Lewin2023-01-31T16:48:49+00:00Events, Thought Leadership|

Cell & gene therapy advancement has increased at an immense rate over the past decade. With the right tools and guidance, patients can receive new forms of treatments. Staying up to date with progress in the field is as important as ever with the constant strive to improve technology, especially in areas like regulatory pathways, novel technologies, and CMC and manufacturing trends.

Sponsored by Precision ADVANCE, this Life Science Connect webinar will convene leading advanced therapy experts to discuss innovation and expectations for advanced therapies in 2023. This discussion will be moderated by Andy Kinley (VP of Innovation & Clinical Science, Precision for Medicine), and include insights from Peter Andersen (CSO, Vita Therapeutics), Deb Phippard (CSO, Precision for Medicine), Palani Palaniappan (CTO, Flagship Pioneering), Phil Cyr (SVP, Precision Value & Health), and Charlie Harper (VP, Project Farma).

(more…)

De-risking Market Launch: Leveraging HEOR Evidence Planning to Support Informed Payer Decisions

Lisa Lewin2023-02-21T21:15:39+00:00Thought Leadership|

HEOR data can help to close knowledge gaps and uncertainties that payers may possess when making decisions involving access and reimbursement. Precision’s Jacquelyn Chou, Alexandria Portelli and Andrew Cournoyer discuss important steps in prelaunch HEOR planning to support a successful market launch.

READ THE ARTICLE HERE!

PRECISION VALUE & HEALTH NAMES DOUG FULLING PRESIDENT

Lisa Lewin2023-01-28T18:00:54+00:00Events, News|

Proven Life Sciences Leader Takes Reins to Continue Rapid Growth and
Drive Next-Gen Commercialization Model

BETHESDA, MD (January 26, 2023) Precision Value & Health (PVH), today announces that Doug Fulling has joined as President. As the industry leader in delivering complementary, integrated and specialized capabilities across the commercialization continuum, Doug will be accountable for the overall strategy, organizational leadership, financial performance, and next-level growth of this market-leading commercial enterprise.

(more…)

White Paper: Achieving Launch Excellence: A Novel Data- and Analytics-Informed Approach

Lisa Lewin2023-01-21T00:56:23+00:00Thought Leadership|

Data and analytics can help drive and inform launch preparations and support efforts to achieve launch excellence through realistic goal-setting and risk mitigation. PRECISIONadvisors works with manufacturers, helping them make key decisions—related to product positioning, go-to-market strategy, and customer engagement across payers, providers, prescribers, and patients—through data- and analytics-driven insights.

Learn how an integrated data-driven approach can set realistic goals and de-risk your launch.

DOWNLOAD THE WHITEPAPER HERE!

Prescription Drug Inflation Rebates: The Inflation Reduction Act Impact Just Around The Corner

Lisa Lewin2023-01-20T17:36:40+00:00Thought Leadership|

More and more genetic tests are coming onto the market to help make sure the right patient gets the right drug at the right time. However, the sheer volume of these tests may be overwhelming payers in their coverage decisions. Precision’s Erin Lopata and others weigh in on the need for shareholders to work together to help establish the clinical utility that payers need to make coverage decisions on genetic tests.

READ THE ARTICLE HERE!

Healthcare Agency Roundtable 2022: Positioning for resiliency: Back to the (virtual) office, building and retaining talent

Lisa Lewin2023-01-27T00:41:00+00:00Thought Leadership|

Precision’s Jenny Love and other industry insiders weigh in on Med Ad New’s “Healthcare Agency Roundtable 2022: Positioning for resiliency: Back to the (virtual) office, building and retaining talent.”

READ THE ARTICLE HERE!

Early Health Economic Models in Gene and Cell Therapy to Inform Clinical Trial Design and Optimize Commercialization Efforts

Lisa Lewin2023-02-21T20:59:36+00:00Events, Thought Leadership|

Since the early 2000s, early economic models have been used by many developers as a best practice to maximize development through clinical trial design and commercial success. Early economic models are similar to HTA models in that they assess the direct and indirect costs and consequences of using a new therapy. Based off experience, early health economic models have been particularly useful in three major areas.

Assessing commercial viability
Developing clinical trial design and evidence-generation strategy
Planning for launch preparedness

Ivar Jensen (VP, Precisionheor) is joined by Phil Cyr (SVP, Precision Value & Health) to provide insight on this in “Early Health Economic Models in Gene and Cell Therapy to Inform Clinical Trial Design and Optimize Commercialization Efforts“.

CLICK HERE to read the full article

Collaboration is Needed Among Stakeholders for Genetic Tests to be Beneficial

Lisa Lewin2023-01-19T14:36:43+00:00Thought Leadership|

More and more genetic tests are coming onto the market to help make sure the right patient gets the right drug at the right time. However, the sheer volume of these tests may be overwhelming payers in their coverage decisions. Precision’s Erin Lopata and others weigh in on the need for shareholders to work together to help establish the clinical utility that payers need to make coverage decisions on genetic tests.

READ THE ARTICLE HERE!

40 Under 40: Ashwin Athri and Isabella Sergio

Lisa Lewin2023-01-19T14:07:59+00:00Events, Thought Leadership|

We’re excited to announce that two of our Precision colleagues have been named to MM+M’s 40 Under 40 this year! Congratulations to Ashwin Athri, EVP, Managing Director, PRECISIONxtract, and Isabella Sergio, EVP, Managing Director, PRECISIONvalue. Now in its fourth year, 40 Under 40 honors the industry’s best-regarded young talent. We look forward to celebrating with Ashwin and Isabella, and all the other honorees, on February 16.

About Lisa Lewin